Simulation Modeling of Oral Cancer Development with Risk Stratification: How Potential Screening Programs Can Be Evaluated.

IF 1.7 Q3 HEALTH CARE SCIENCES & SERVICES
MDM Policy and Practice Pub Date : 2025-08-19 eCollection Date: 2025-07-01 DOI:10.1177/23814683251353226
Mutita Siriruchatanon, Emily R Brooks, Alexander R Kerr, Denise M Laronde, Miriam P Rosin, Stella K Kang
{"title":"Simulation Modeling of Oral Cancer Development with Risk Stratification: How Potential Screening Programs Can Be Evaluated.","authors":"Mutita Siriruchatanon, Emily R Brooks, Alexander R Kerr, Denise M Laronde, Miriam P Rosin, Stella K Kang","doi":"10.1177/23814683251353226","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background.</b> A barrier to early-stage oral cavity cancer detection is the lack of a defined population and screening regimen satisfying risk-benefit considerations. <b>Methods.</b> We constructed a microsimulation model, Simulation of Cancers of the Oral cavity and Risk Exposures (SCORE), that incorporates risk profiles defined by smoking and alcohol exposure. SCORE simulates the development and progression of oral potentially malignant disorders (OPMD) representing benign, dysplastic, or malignant lesions in the US population starting at age 40 y. OPMD high-risk characteristics of malignant transformation informed a biopsy decision rule. SCORE was calibrated to national cancer registry data. We compared life expectancy in those aged 40 to 60 y with OPMDs, cancer incidence, and cancer-specific deaths across screening strategies with and without the biopsy decision rule, assuming screening every 3 y starting at age 50 y. <b>Results.</b> In US men, all screening strategies reduced cancer incidence and cancer-specific mortality by at least 26% and 20% compared with no screening. Whether with or without a biopsy decision rule, life expectancy among those aged 40 to 60 y with OPMDs was 36.37 ± 0.01 life-years, a gain of 0.03 life-years. However, the use of the biopsy rule improved diagnostic efficiency with 8 biopsies per treatable diagnosis. Screening with or without the biopsy decision rule in high-risk men demonstrated comparable benefit, reducing cancer-specific deaths by 27% and incidence by 20% compared with no screening. Meanwhile, in the non-high-risk subpopulation, applying the biopsy rule avoided the harms of excess procedures, reducing lifetime biopsies by 38% versus biopsy of all OPMDs while preserving reductions in cancer burden. <b>Conclusions.</b> SCORE enables virtual trials of various screening regimens and target populations. Given the time and cost of clinical trials, SCORE may facilitate the evaluation of new technologies and clinical recommendations.</p><p><strong>Highlights: </strong>A new oral cancer simulation model with risk factors including degrees of smoking and alcohol exposure, oral lesion features, and sex incorporates more accurate and precise representation of patient risk categories.We evaluated screening strategies for oral potentially malignant disorders with or without risk-stratified biopsy referral in both the general population and subpopulations defined by degrees of smoking and alcohol exposure.Men with a high degree of both smoking and alcohol exposure exhibited a significant reduction in cancer-specific deaths and cancer incidence from screening programs for oral potentially malignant disorders.Screening with risk-stratified biopsy, using a surgical treatment threshold of moderate dysplasia or worse, yielded the greatest efficiency in term of biopsies needed to detect 1 treatable case.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"10 2","pages":"23814683251353226"},"PeriodicalIF":1.7000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12368318/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MDM Policy and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/23814683251353226","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background. A barrier to early-stage oral cavity cancer detection is the lack of a defined population and screening regimen satisfying risk-benefit considerations. Methods. We constructed a microsimulation model, Simulation of Cancers of the Oral cavity and Risk Exposures (SCORE), that incorporates risk profiles defined by smoking and alcohol exposure. SCORE simulates the development and progression of oral potentially malignant disorders (OPMD) representing benign, dysplastic, or malignant lesions in the US population starting at age 40 y. OPMD high-risk characteristics of malignant transformation informed a biopsy decision rule. SCORE was calibrated to national cancer registry data. We compared life expectancy in those aged 40 to 60 y with OPMDs, cancer incidence, and cancer-specific deaths across screening strategies with and without the biopsy decision rule, assuming screening every 3 y starting at age 50 y. Results. In US men, all screening strategies reduced cancer incidence and cancer-specific mortality by at least 26% and 20% compared with no screening. Whether with or without a biopsy decision rule, life expectancy among those aged 40 to 60 y with OPMDs was 36.37 ± 0.01 life-years, a gain of 0.03 life-years. However, the use of the biopsy rule improved diagnostic efficiency with 8 biopsies per treatable diagnosis. Screening with or without the biopsy decision rule in high-risk men demonstrated comparable benefit, reducing cancer-specific deaths by 27% and incidence by 20% compared with no screening. Meanwhile, in the non-high-risk subpopulation, applying the biopsy rule avoided the harms of excess procedures, reducing lifetime biopsies by 38% versus biopsy of all OPMDs while preserving reductions in cancer burden. Conclusions. SCORE enables virtual trials of various screening regimens and target populations. Given the time and cost of clinical trials, SCORE may facilitate the evaluation of new technologies and clinical recommendations.

Highlights: A new oral cancer simulation model with risk factors including degrees of smoking and alcohol exposure, oral lesion features, and sex incorporates more accurate and precise representation of patient risk categories.We evaluated screening strategies for oral potentially malignant disorders with or without risk-stratified biopsy referral in both the general population and subpopulations defined by degrees of smoking and alcohol exposure.Men with a high degree of both smoking and alcohol exposure exhibited a significant reduction in cancer-specific deaths and cancer incidence from screening programs for oral potentially malignant disorders.Screening with risk-stratified biopsy, using a surgical treatment threshold of moderate dysplasia or worse, yielded the greatest efficiency in term of biopsies needed to detect 1 treatable case.

Abstract Image

Abstract Image

Abstract Image

口腔癌发展的风险分层模拟建模:如何评估潜在的筛查方案。
背景。早期口腔癌检测的一个障碍是缺乏确定的人群和满足风险-收益考虑的筛查方案。方法。我们构建了一个微观模拟模型,模拟口腔癌和风险暴露(SCORE),其中包含由吸烟和酒精暴露定义的风险概况。SCORE模拟40岁开始的美国人群中口腔潜在恶性疾病(OPMD)的发展和进展,代表良性、发育不良或恶性病变。OPMD恶性转化的高风险特征为活检决策规则提供了依据。SCORE根据国家癌症登记数据进行校准。我们比较了40 - 60岁opmd患者的预期寿命、癌症发病率和癌症特异性死亡,采用和不采用活检决策规则的筛查策略,假设从50岁开始每3年筛查一次。在美国男性中,与不进行筛查相比,所有筛查策略都能降低癌症发病率和癌症特异性死亡率至少26%和20%。无论有无活检决策规则,40 ~ 60岁opmd患者的预期寿命为36.37±0.01生命年,增加0.03生命年。然而,活检规则的使用提高了诊断效率,每个可治疗的诊断进行8次活检。在高风险男性中,采用或不采用活检决定规则进行筛查显示出相当的益处,与不进行筛查相比,癌症特异性死亡率降低27%,发病率降低20%。与此同时,在非高危亚人群中,应用活检规则避免了过度手术的危害,与所有opmd的活检相比,减少了38%的终生活检,同时保持了癌症负担的减少。结论。SCORE可以对各种筛查方案和目标人群进行虚拟试验。考虑到临床试验的时间和成本,SCORE可以促进对新技术和临床建议的评估。一个新的口腔癌模拟模型,包括吸烟和酒精暴露程度、口腔病变特征和性别等危险因素,更准确和精确地表示患者的风险类别。我们评估了在普通人群和根据吸烟和酒精暴露程度定义的亚人群中,有或没有风险分层活检转诊的口腔潜在恶性疾病的筛查策略。高度吸烟和酒精暴露的男性在口腔潜在恶性疾病筛查项目中显示出癌症特异性死亡和癌症发病率的显著降低。采用风险分层活检筛查,采用中度发育不良或更严重的手术治疗阈值,在检测1例可治疗病例所需的活检方面产生了最大的效率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
MDM Policy and Practice
MDM Policy and Practice Medicine-Health Policy
CiteScore
2.50
自引率
0.00%
发文量
28
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信